152 related articles for article (PubMed ID: 30068530)
1. Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.
Janovick JA; Spicer TP; Bannister TD; Smith E; Ganapathy V; Scampavia L
Biochem J; 2018 Sep; 475(18):2941-2953. PubMed ID: 30068530
[TBL] [Abstract][Full Text] [Related]
2. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
4. Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus.
Smith E; Janovick JA; Bannister TD; Shumate J; Scampavia L; Conn PM; Spicer TP
J Biomol Screen; 2016 Sep; 21(8):824-31. PubMed ID: 27280550
[TBL] [Abstract][Full Text] [Related]
5. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.
Janovick JA; Spicer TP; Bannister TD; Scampavia L; Conn PM
PLoS One; 2017; 12(8):e0181830. PubMed ID: 28767678
[TBL] [Abstract][Full Text] [Related]
8. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
9. Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.
Janovick JA; Spicer TP; Smith E; Bannister TD; Kenakin T; Scampavia L; Conn PM
Mol Cell Endocrinol; 2016 Oct; 434():176-85. PubMed ID: 27389877
[TBL] [Abstract][Full Text] [Related]
10. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
Erdélyi LS; Balla A; Patócs A; Tóth M; Várnai P; Hunyady L
Mol Endocrinol; 2014 May; 28(5):634-43. PubMed ID: 24628417
[TBL] [Abstract][Full Text] [Related]
11. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
Ando F; Mori S; Yui N; Morimoto T; Nomura N; Sohara E; Rai T; Sasaki S; Kondo Y; Kagechika H; Uchida S
Nat Commun; 2018 Apr; 9(1):1411. PubMed ID: 29650969
[TBL] [Abstract][Full Text] [Related]
12. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
[TBL] [Abstract][Full Text] [Related]
15. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
Rochdi MD; Vargas GA; Carpentier E; Oligny-Longpré G; Chen S; Kovoor A; Gitelman SE; Rosenthal SM; von Zastrow M; Bouvier M
Mol Pharmacol; 2010 May; 77(5):836-45. PubMed ID: 20159941
[TBL] [Abstract][Full Text] [Related]
17. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
18. A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
Miyakoshi M; Kamoi K; Uchida S; Sasaki S
Endocr J; 2003 Dec; 50(6):809-14. PubMed ID: 14709855
[TBL] [Abstract][Full Text] [Related]
19. V2 vasopressin receptor mutations.
Makita N; Manaka K; Sato J; Iiri T
Vitam Horm; 2020; 113():79-99. PubMed ID: 32138955
[TBL] [Abstract][Full Text] [Related]
20. A low-affinity vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus.
Yokoyama K; Yamauchi A; Izumi M; Itoh T; Ando A; Imai E; Kamada T; Ueda N
J Am Soc Nephrol; 1996 Mar; 7(3):410-4. PubMed ID: 8704106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]